I write short fiction, spend time in my garden and bake. Winner Oxford Flash Fiction "New Voice". Mammy to one.
Today we introduce two new upcoming studies from SITU NDS:
COMBAT-GB 🧠
RECURRENT-GB 🧠
These studies will aim to answer important questions on Glioblastoma management.
Today we introduce FORENSIC!
FORENSIC will assess if treating low back pain with surgery is better than nonsurgical treatment, and also aims to find out if the spinal fusion surgery is good value for money for the NHS. 🏥
🌐 forensic.octru.ox.ac.uk
Today we introduce FORENSIC!
FORENSIC will assess if treating low back pain with surgery is better than nonsurgical treatment, and also aims to find out if the spinal fusion surgery is good value for money for the NHS. 🏥
🌐 forensic.octru.ox.ac.uk
Thank you to all our recruiting sites for support of the trial: @ouhospitals.bsky.social @gstt-nhs.bsky.social
@cuh.nhs.uk @nottmhospitals.bsky.social
@nhsgrampian.bsky.social @uhsft.bsky.social & Uni Hospitals Leicester
#TP53 #LFS
Thank you to all our recruiting sites for support of the trial: @ouhospitals.bsky.social @gstt-nhs.bsky.social
@cuh.nhs.uk @nottmhospitals.bsky.social
@nhsgrampian.bsky.social @uhsft.bsky.social & Uni Hospitals Leicester
#TP53 #LFS
Today we introduce MILI
MILI is a clinical trial investigating the use of a drug called metformin as a way of reducing the cancer risk in people with Li Fraumeni Syndrome (LFS)
Find out more: mili.octru.ox.ac.uk
@octooxford.bsky.social
Today we introduce MILI
MILI is a clinical trial investigating the use of a drug called metformin as a way of reducing the cancer risk in people with Li Fraumeni Syndrome (LFS)
Find out more: mili.octru.ox.ac.uk
@octooxford.bsky.social
Each week will feature a different team member.
We are starting off with the brains behind the trial, our very own Clinical Investigator, Prof Sarah Blagden:
#LFS #LiFraumeni @oncology.ox.ac.uk @oxfordcancer.bsky.social
tp53.co.uk/lfs-tp53/
Each week will feature a different team member.
We are starting off with the brains behind the trial, our very own Clinical Investigator, Prof Sarah Blagden:
#LFS #LiFraumeni @oncology.ox.ac.uk @oxfordcancer.bsky.social
tp53.co.uk/lfs-tp53/
Thank you to everyone taking part in all of our studies, and to all of our study teams & sites.
Thank you to everyone taking part in all of our studies, and to all of our study teams & sites.
We'd like to close today by thanking everyone who takes part in our research and everyone who makes it possible - we couldn't do it without you!
#InternationalClinicalTrialsDay2025 #ICTD2025
We'd like to close today by thanking everyone who takes part in our research and everyone who makes it possible - we couldn't do it without you!
#InternationalClinicalTrialsDay2025 #ICTD2025
Today we will be sharing thoughts from the OCTRU Hub team on Clinical Trials, and what they mean to them!
#InternationalClinicalTrialsDay2025 #ICTD2025
Today we will be sharing thoughts from the OCTRU Hub team on Clinical Trials, and what they mean to them!
#InternationalClinicalTrialsDay2025 #ICTD2025
academic.oup.com/jid/advance-...
academic.oup.com/jid/advance-...
📢 YPAG member Fiorella: 'It's shown me the bigger picture - how science can be used to make a difference.'
Find out more about the group & its members 👇
#WomenInScience
📢 YPAG member Fiorella: 'It's shown me the bigger picture - how science can be used to make a difference.'
Find out more about the group & its members 👇
#WomenInScience
Today's molnupiravir findings follow on from research published by our team earlier this year which found the recommended 5-day course of treatment might not be long enough to clear the virus 👇 #NDPCHSReview24
www.phc.ox.ac.uk/news/new-stu...
Today's molnupiravir findings follow on from research published by our team earlier this year which found the recommended 5-day course of treatment might not be long enough to clear the virus 👇 #NDPCHSReview24
www.phc.ox.ac.uk/news/new-stu...